HRP921454A2 - Stable salts of (1r,2s)-2-n-(2-hydroxylamino-2-oxoethyl)-n-methyl-amino onyl cyclohexane-1-carboxylic acid, process for their aration and pharmaceutical compositions containing them - Google Patents
Stable salts of (1r,2s)-2-n-(2-hydroxylamino-2-oxoethyl)-n-methyl-amino onyl cyclohexane-1-carboxylic acid, process for their aration and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- HRP921454A2 HRP921454A2 HR921454A HRP921454A HRP921454A2 HR P921454 A2 HRP921454 A2 HR P921454A2 HR 921454 A HR921454 A HR 921454A HR P921454 A HRP921454 A HR P921454A HR P921454 A2 HRP921454 A2 HR P921454A2
- Authority
- HR
- Croatia
- Prior art keywords
- oxoethyl
- cyclohexane
- carboxylic acid
- methylamino
- carbonyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 20
- 150000003839 salts Chemical class 0.000 title claims description 16
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 16
- QKIVRALZQSUWHH-SFYZADRCSA-N (1s,2r)-2-[[2-(hydroxyamino)-2-oxoethyl]-methylcarbamoyl]cyclohexane-1-carboxylic acid Chemical class ONC(=O)CN(C)C(=O)[C@@H]1CCCC[C@@H]1C(O)=O QKIVRALZQSUWHH-SFYZADRCSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 8
- 238000005984 hydrogenation reaction Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Chemical group 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical group CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 239000003245 coal Substances 0.000 claims 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 5
- NUOJQKMZSQNWGI-CNYCQXTOSA-N (1S,2R)-2-[[1-(hydroxyamino)-2-oxo-3-phenylpropyl]-methylcarbamoyl]cyclohexane-1-carboxylic acid Chemical compound O=C([C@H]1[C@H](CCCC1)C(O)=O)N(C)C(NO)C(=O)CC1=CC=CC=C1 NUOJQKMZSQNWGI-CNYCQXTOSA-N 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000012435 analytical chromatography Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000003821 enantio-separation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001176 L-lysyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229950010375 idrapril Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000012262 resinous product Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI913448A IT1252708B (it) | 1991-12-23 | 1991-12-23 | Sali stabili dell'acido (+)-(1r,2s)-2((n-(2-idrossilammino-2-ossoetil)-n-metilammino)carbonil)cicloesan-1-carbossilico,ad attivita' ace inibitrice, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP921454A2 true HRP921454A2 (en) | 1995-02-28 |
Family
ID=11361409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR921454A HRP921454A2 (en) | 1991-12-23 | 1992-12-22 | Stable salts of (1r,2s)-2-n-(2-hydroxylamino-2-oxoethyl)-n-methyl-amino onyl cyclohexane-1-carboxylic acid, process for their aration and pharmaceutical compositions containing them |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0575572A1 (pt) |
| JP (1) | JPH06506002A (pt) |
| CN (1) | CN1079474A (pt) |
| AU (1) | AU657591B2 (pt) |
| BG (1) | BG98050A (pt) |
| BR (1) | BR9205652A (pt) |
| CA (1) | CA2104372A1 (pt) |
| CZ (1) | CZ379692A3 (pt) |
| EE (1) | EE9400006A (pt) |
| FI (1) | FI933685A (pt) |
| HR (1) | HRP921454A2 (pt) |
| HU (1) | HUT69287A (pt) |
| IT (1) | IT1252708B (pt) |
| LV (1) | LV10426B (pt) |
| MA (1) | MA22749A1 (pt) |
| MX (1) | MX9207543A (pt) |
| NZ (1) | NZ245547A (pt) |
| PL (1) | PL169086B1 (pt) |
| PT (1) | PT101156A (pt) |
| RU (1) | RU2079489C1 (pt) |
| SI (1) | SI9200409A (pt) |
| SK (1) | SK379692A3 (pt) |
| TN (1) | TNSN92117A1 (pt) |
| WO (1) | WO1993013056A1 (pt) |
| YU (1) | YU110892A (pt) |
| ZA (1) | ZA9210004B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264860B1 (it) * | 1993-06-21 | 1996-10-17 | Guidotti & C Spa Labor | Derivati di acidi cis- e trans-2(((2-(isdrossiammino)-2-ossoetil)- alchilammino)carbonil)cicloesancarbossilici |
| US5639746A (en) * | 1994-12-29 | 1997-06-17 | The Procter & Gamble Company | Hydroxamic acid-containing inhibitors of matrix metalloproteases |
| FR2817241B1 (fr) | 2000-11-30 | 2003-03-07 | Cebal | Tube aluminium avec embout secable |
| CN101516191A (zh) * | 2006-09-28 | 2009-08-26 | 默克公司 | Saha的胺碱盐和其多晶型物 |
| MX2022005016A (es) * | 2020-04-27 | 2022-05-16 | Carter Hoffmann LLC | Sistema de movimiento de puerta para gabinete. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1224627B (it) * | 1988-04-12 | 1990-10-04 | Guidotti & C Spa Labor | Ammidi di acidi ciclometilen_1,2_dicarbossilici adattivita' terapeutica, procedimenti per la loro preparazione e composizioni farmaceutiche che le contengono. |
-
1991
- 1991-12-23 IT ITMI913448A patent/IT1252708B/it active IP Right Grant
-
1992
- 1992-12-12 CA CA002104372A patent/CA2104372A1/en not_active Abandoned
- 1992-12-12 HU HU9302389A patent/HUT69287A/hu unknown
- 1992-12-12 EP EP92924726A patent/EP0575572A1/en not_active Withdrawn
- 1992-12-12 JP JP5511398A patent/JPH06506002A/ja active Pending
- 1992-12-12 WO PCT/EP1992/002903 patent/WO1993013056A1/en not_active Application Discontinuation
- 1992-12-12 RU RU9293052414A patent/RU2079489C1/ru active
- 1992-12-12 AU AU30871/92A patent/AU657591B2/en not_active Ceased
- 1992-12-12 BR BR9205652A patent/BR9205652A/pt not_active Application Discontinuation
- 1992-12-21 NZ NZ245547A patent/NZ245547A/en unknown
- 1992-12-21 SK SK3796-92A patent/SK379692A3/sk unknown
- 1992-12-21 CZ CS923796A patent/CZ379692A3/cs unknown
- 1992-12-22 HR HR921454A patent/HRP921454A2/hr not_active Application Discontinuation
- 1992-12-22 MA MA23040A patent/MA22749A1/fr unknown
- 1992-12-22 SI SI9200409A patent/SI9200409A/sl unknown
- 1992-12-23 PT PT101156A patent/PT101156A/pt not_active Application Discontinuation
- 1992-12-23 PL PL92297118A patent/PL169086B1/pl unknown
- 1992-12-23 ZA ZA9210004A patent/ZA9210004B/xx unknown
- 1992-12-23 YU YU110892A patent/YU110892A/sh unknown
- 1992-12-23 TN TNTNSN92117A patent/TNSN92117A1/fr unknown
- 1992-12-23 MX MX9207543A patent/MX9207543A/es unknown
- 1992-12-23 LV LVP-92-358A patent/LV10426B/lv unknown
- 1992-12-23 CN CN92113839A patent/CN1079474A/zh active Pending
-
1993
- 1993-08-18 BG BG98050A patent/BG98050A/bg unknown
- 1993-08-20 FI FI933685A patent/FI933685A/fi not_active Application Discontinuation
-
1994
- 1994-05-23 EE EE9400006A patent/EE9400006A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX9207543A (es) | 1993-08-01 |
| FI933685A0 (fi) | 1993-08-20 |
| CZ379692A3 (en) | 1993-09-15 |
| LV10426A (lv) | 1995-02-20 |
| HUT69287A (en) | 1995-09-28 |
| NZ245547A (en) | 1995-12-21 |
| CA2104372A1 (en) | 1993-06-24 |
| AU657591B2 (en) | 1995-03-16 |
| MA22749A1 (fr) | 1993-07-01 |
| YU110892A (sh) | 1996-01-08 |
| WO1993013056A1 (en) | 1993-07-08 |
| ITMI913448A0 (it) | 1991-12-23 |
| PL169086B1 (pl) | 1996-05-31 |
| PT101156A (pt) | 1994-06-30 |
| ZA9210004B (en) | 1993-12-13 |
| CN1079474A (zh) | 1993-12-15 |
| SK379692A3 (en) | 1995-04-12 |
| TNSN92117A1 (fr) | 1993-06-08 |
| BR9205652A (pt) | 1994-05-03 |
| IT1252708B (it) | 1995-06-26 |
| EE9400006A (et) | 1995-12-15 |
| FI933685A (fi) | 1993-08-20 |
| HU9302389D0 (en) | 1993-11-29 |
| AU3087192A (en) | 1993-07-28 |
| LV10426B (en) | 1995-08-20 |
| PL297118A1 (en) | 1993-09-06 |
| BG98050A (bg) | 1994-04-29 |
| EP0575572A1 (en) | 1993-12-29 |
| ITMI913448A1 (it) | 1993-06-23 |
| JPH06506002A (ja) | 1994-07-07 |
| RU2079489C1 (ru) | 1997-05-20 |
| SI9200409A (en) | 1993-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nishizawa et al. | Synthesis and structure-activity relations of bestatin analogs, inhibitors of aminopeptidase B | |
| Bernatowicz et al. | 1H-Pyrazole-1-carboxamidine hydrochloride an attractive reagent for guanylation of amines and its application to peptide synthesis | |
| WEBER et al. | Comparison of the photochemical behavior of four different photoactivatable probes | |
| Hofmann et al. | Studies on Polypeptides. VII. The Synthesis of Peptides Containing Arginine1 | |
| Wyvratt et al. | Reductive amination of ethyl 2-oxo-4-phenylbutanoate with L-alanyl-L-proline. Synthesis of enalapril maleate | |
| Szirtes et al. | Synthesis of thyrotropin-releasing hormone analogs. 1. Complete dissociation of central nervous system effects from thyrotropin-releasing activity | |
| Holley et al. | The Synthesis of L-Histidyl Peptides1 | |
| EP3797795A1 (en) | Preparation process of antibody drug conjugate intermediate | |
| CS247159B2 (en) | Method of cis,endo-2-azabicyclo(3,3,1) octal-3-carboxyl acid's derivatives production | |
| Deseke et al. | Intrinsic reactivities of amino acids towards photoalkylation with benzophenone− a study preliminary to photolabelling of the transmembrane protein glycophorin A | |
| HRP921454A2 (en) | Stable salts of (1r,2s)-2-n-(2-hydroxylamino-2-oxoethyl)-n-methyl-amino onyl cyclohexane-1-carboxylic acid, process for their aration and pharmaceutical compositions containing them | |
| Stark | [29] Sequential degradation of peptides and proteins from their COOH termini with ammonium thiocyanate and acetic anhydride | |
| Li et al. | The synthesis of L-histidyl-L-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and L-histidyl-D-phenylalanyl-L-ornithyl-L-tryptophyl-glycine and their melanocyte-stimulating activity | |
| Jain et al. | Synthesis and biology of new thyrotropin-releasing hormone (TRH) analogues | |
| EP0363964B1 (en) | Benzotriazole derivatives and chiral derivatization reagents for carboxylic acids thereof | |
| CA1231719A (en) | Synthesis of phenyl alanine derivatives | |
| US20130143262A1 (en) | Method for producing peptide | |
| Rizo et al. | Use of polar picolyl protecting groups in peptide synthesis | |
| US3178472A (en) | Preparation of optically active naturally occurring n-monomethyl-amino carboxylic acids | |
| CZ24594A3 (en) | Aminoascorbic acid derivatives, process of their preparation and their use | |
| EP0110484B1 (en) | Derivatives of aminopyridinecarboxylic acids, methods for their preparation and pharmaceutical compositions containing them | |
| HRP20000683A2 (en) | Process for the production of r-(+)-6-carboxamido-3-n-methylamino-1,2,3,4-tetrahydrocarbazole | |
| Saghyan et al. | New generations of optically active non-proteinogenic α-amino acids, synthesis and study | |
| JP2568635B2 (ja) | 塩基性アミド化合物 | |
| EP1048674A1 (en) | Method for separating and purifying aspartame and aspartame derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 19951222 Year of fee payment: 4 |
|
| ODBC | Application rejected |